Industry·June 1, 2026

Gene Therapy Medications Pose Financial Challenges for Health Plans

Metabolic gene therapies are creating new financial pressures for health plans and benefits managers. These treatments offer clinical benefits for patients with serious conditions but carry high costs that require specialized coverage and payment strategies. The article discusses how plans must prepare benefits structures to manage these emerging high-cost therapies. No specific implementation timeline or regulatory action is described.

Why it matters for managed care

Medicaid MCOs will need to develop utilization management protocols, negotiate manufacturer arrangements, and potentially restructure capitation agreements to account for gene therapy costs that can exceed $1 million per patient.

Managed Care · Pharmacy · Finance

Read the full article at medcitynews.com →

Share this briefing